menu search

Kura oncology announces three presentations at aacr-nci-eortc international conference on molecular targets and cancer therapeutics

– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, ...

October 4, 2023, 11:30 am

Mirati (mrtx) down 7% on chmp's opinion on krazati filing

Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in krasg12c mutated NSCLC does not fulfill ...

July 24, 2023, 1:05 pm

Frontier medicines presents new preclinical data on its development candidate, fmc-376, a dual krasg12c inhibitor, at the 2023 aacr annual meeting

-FMC-376 is a highly selective, direct dual inhibitor designed to rapidly and completely block both the active and inactive forms of ...

April 16, 2023, 7:00 pm

Revolution medicines reports fourth quarter and full year 2022 financial results and update on corporate progress

Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-...

February 27, 2023, 9:05 pm

Mirati's (mrtx) stock rallies 11% on buyout speculations

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated ...

November 24, 2022, 12:02 pm

Mirati therapeutics' adagrasib application under fda review for lung cancer setting

The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lu...

February 16, 2022, 8:21 am

Mirati therapeutics' adagrasib application under fda review for lung cancer setting

The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lu...

February 16, 2022, 8:21 am

Mirati therapeutics' adagrasib application under fda review for lung cancer setting

The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lu...

February 16, 2022, 8:21 am

Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...

January 21, 2022, 12:14 pm

Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...

January 21, 2022, 12:14 pm

Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...

January 21, 2022, 12:14 pm


Search within

Pages Search Results: